@article{1f576d5371974d76bc163940181aeb62,
title = "Characteristics of morphologic macular abnormalities in neuroimmunology practice",
abstract = " Background: Morphologic macular abnormalities (MMAs) are frequently seen on macular optical coherence tomography (OCT) imaging in neuroimmunology practice, yet studies pragmatically assessing prevalence and risk factors of MMAs to date are limited. Objective: To describe the characteristics of MMAs in a neuroimmunology-based academic practice. Methods: Cross-sectional study of 1450 patients (2900 eyes) who underwent spectral-domain macular OCT between June 2010 and June 2012. The association between MMAs and demographic variables was analyzed using mixed-effects logistic regression. Odds ratios (ORs) were calculated per 5-year age increments. Results: MMAs were observed in 338/2872 eyes (11.7%) of 232/1445 participants (16.1%). The most common abnormalities identified, included drusen (6.0%), epiretinal membrane (ERM; 5.5%), and microcystoid macular pathology (MMP; 1.9%). Overall, patients with MMAs were older (OR: 1.79, p = 5 × 10 –5 ) and more likely to be males (OR: 2.45, p = 0.014). In particular, advancing age was associated with higher risk of drusen and ERM (OR: 1.80 and 4.26, p = 2 × 10 –5 and 7 × 10 –3 , respectively). MMP prevalence declined with age (OR: 0.73, p = 0.015) and was associated with African-American ethnicity (OR: 15.0, p = 5 × 10 –5 ). Conclusion: Unexpected or incidental MMAs are common in patients assessed with OCT in neuroimmunology practice, emphasizing the importance of comprehensive OCT image review for risk stratification and appropriate ophthalmology referral. ",
keywords = "Multiple sclerosis, drusen, epiretinal membrane, microcystoid macular pathology, neuromyelitis optica, optical coherence tomography",
author = "Omar Al-Louzi and Sotirchos, {Elias S.} and Angela Vidal-Jordana and Beh, {Shin C.} and Julia Button and Howard Ying and Balcer, {Laura J.} and Frohman, {Elliot M.} and Shiv Saidha and Calabresi, {Peter A.} and Newsome, {Scott D.}",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/ or publication of this article: O.A.-L., E.S.S., S.C.B., H.S.Y., and J.B. report no disclosures. A.V.-J. has received speaking honoraria from Sanofi-Aventis and Novartis and has received consulting fees from Biogen-Idec and Roche. L.J.B. has received consulting honoraria from Biogen. E.M.F. has received speaker and consulting fees from Novartis, Genzyme, Acorda, and TEVA. P.A.C. has received personal compensation for consulting and serving on scientific advisory boards from Vertex, Vaccinex, Merck, and Abbvie, and has received research funding from Biogen-IDEC, MedImmune, and Novartis. S.S. has received consulting fees from Medical Logix for the development of CME programs in neurology, consulting fees from Axon Advisors LLC, Educational Grant Support from Novartis & Teva Neurosciences, speaking honoraria from the National Association of Managed Care Physicians, Family Medicine Foundation of West Virginia, and Advanced Studies in Medicine, and served on a scientific advisory board for Biogen-Idec, Genzyme, and Novartis. He also receives research funding from the Race to Erase MS and Genentech Corporation. S.D.N. has received consultant fees for scientific advisory boards from Biogen and Genentech and has received research funding (paid directly to institution) from Biogen, Novartis, Genentech, Department of Defense, and the National MS Society. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by a Race to Erase MS grant to S.S. and National Institutes of Health grant 5R01NS082347 to P.A.C.",
year = "2019",
month = mar,
day = "1",
doi = "10.1177/1352458517741206",
language = "English (US)",
volume = "25",
pages = "361--371",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "3",
}